cbimportant times indeedfrom the recent rights issue paper...

cb
important times indeed

from the recent rights issue paper work..."This triggers
the start of the data analysis which should deliver the initial Phase III results from the trial in the 2nd quarter of 2009.
Avexa will take the result of this component of the trial for
review at the FDA."

so the timing of feedback from the fda should be fitted in your timetable of upcoming events...